The DEA Telemedicine Flexibilities End December 31, 2026: What Could Happen January 1 to Testosterone, Ketamine and Phentermine Programs
The DEA telemedicine flexibilities that let clinicians prescribe controlled substances without an in-person visit end on December 31, 2026. As of October 25, no further extension has been announced and the final special registration rule has not been published. Here is what is known and how to plan.
Key Highlights
- The Fourth Temporary Extension lets DEA-registered practitioners prescribe Schedule II to V controlled substances by telemedicine without an in-person evaluation through December 31, 2026, and its text says nothing about what happens after.
- As of October 25, 2026, we found no fifth extension announced or filed, though DEA has extended at the last minute before, and the final special registration rule has been under White House review since August 25, 2026 with its text not public.
- If the flexibilities lapse and nothing replaces them, the statutory baseline returns, which generally requires at least one in-person evaluation before prescribing controlled substances by telemedicine, so patients evaluated only by video would be affected.
- Clinics should map their controlled-substance patients, plan for several outcomes and talk to the medical director before December, since the outcome is not yet known.
Testosterone, ketamine and phentermine are controlled substances, and a good share of cash-pay telehealth programs are built on prescribing them without an in-person visit. That model currently rests on a temporary DEA rule that expires on December 31, 2026. As of October 25, 2026, the next step has not been announced.
This article sets out what is known, what is not and how a clinic can plan without guessing.
What the Current Rule Allows
The Fourth Temporary Extension, published in the Federal Register on December 31, 2025, is effective from January 1, 2026 through December 31, 2026. Under it, a DEA-registered practitioner may prescribe Schedule II through V controlled substances via telemedicine without having conducted an in-person medical evaluation of the patient, if conditions are met. The prescription must be for a legitimate medical purpose in the usual course of professional practice, the visit must use an interactive telecommunications system, the practitioner must be authorized under their DEA registration for that class of drug and the prescription must be consistent with DEA's prescription rules.
The rule says the extension gives DEA time to write a final set of regulations. It says nothing about what happens after December 31, 2026.
What Has and Has Not Been Announced
We found no announcement of a fifth extension as of October 25, 2026, and a search of the Federal Register found no such document filed. Trade press reported that DEA has not stated its plans. DEA has extended at the last minute before: the prior extensions were announced in October 2023 and November 2024, and the most recent was published on the last day of 2025. That is a pattern, not a commitment, and a clinic cannot count on it.
- A final special registration rule: a rule titled Special Registrations for Telemedicine and Limited State Telemedicine Registrations has been under White House review since August 25, 2026, and the federal regulatory agenda lists final action for November 2026. The submitted text is not public.
- What the 2025 proposal said: the January 2025 proposal described three special registrations, each with an $888 fee and a three-year cycle: one for Schedule III through V, one for Schedule II through V limited to listed specialties and one for telemedicine platforms. It proposed a cap on special-registration Schedule II prescriptions, and a DEA-issued state telemedicine registration for each state where patients are treated, at $50 per state for clinicians.
- What is not known: whether the final rule will match the proposal, when it would take effect and whether there will be a transition period.
What Could Happen on January 1 If Nothing Is Finalized
The temporary rule lapses at the end of December 31, 2026, and the underlying statute applies again. Under 21 U.S.C. 829(e), a valid prescription for a controlled substance delivered over the internet generally requires that the practitioner has conducted at least one in-person medical evaluation of the patient, or that a covering practitioner has, with listed exceptions for situations such as a patient in a DEA-registered hospital or clinic or in the physical presence of a registered practitioner.
That is our reading of the statute and the rule text, not a DEA statement about January 1, and it should be confirmed with counsel. On that reading, a new patient seen only by video could not be prescribed Schedule II through V medications by telemedicine, while a patient who had already been evaluated in person by the same practitioner could generally continue by telemedicine, still for a legitimate medical purpose. The buprenorphine and Veterans Affairs final rules are narrow pathways that do not cover testosterone, ketamine or phentermine.
Who Would Feel It Most
- Fully remote testosterone programs: a program that starts patients on video visits only and never sees them in person.
- Ketamine programs: where a prescribing visit happens by video before the patient ever meets the practitioner.
- Weight-loss programs that include phentermine: a Schedule IV drug that sometimes sits alongside GLP-1 programs.
- Multi-state programs: where a practitioner prescribes to patients in several states and also has to deal with state registration rules.
- Programs with no non-controlled alternative: a menu with nothing to offer a patient who cannot be prescribed a controlled drug remotely.
Registration in Each State Is a Separate Question
DEA's guidance says a practitioner prescribing controlled substances to a patient in another state by telemedicine generally must be registered with DEA in the patient's state, with limited exceptions. A COVID-era exception tied to the public health emergency, which ended May 11, 2023, once allowed registration in one state to cover others, and we could not confirm whether it still applies. The 2025 proposal would replace the state-by-state approach with a DEA-issued state telemedicine registration. Until that is settled, the conservative assumption is that each state where a practitioner prescribes controlled substances needs the registrations that state requires.
How to Plan Without Guessing
- Map your controlled-substance patients: list who was evaluated in person by the prescribing practitioner and who was seen only by video, by state.
- Plan for three outcomes: another extension, a final special registration rule with a transition period, or a lapse on January 1, and write down what the clinic would do under each.
- Ask the medical director now: which patients they would continue to prescribe for and under what conditions, and which registrations they hold in which states.
- Add in-person or covered visits where it makes sense: an in-person evaluation, or one with a covered pathway, can change what the clinic may do for a patient.
- Build a non-controlled option: for patients who could not be prescribed a controlled drug by telemedicine, so the clinic is not left without a plan for them.
- Watch the Federal Register and DEA announcements: through December 31, and communicate with patients plainly and early if their care could change.
Where MedGrid Fits
MedGrid connects clinics with physicians licensed in the state where they treat, and the medical director decides which controlled substances a clinic will offer, to whom and under which protocol. If the telemedicine rules change, the director's protocols and the clinic's patient communications change with them. MedGrid supports the administrative side, and the prescribing decisions and registrations stay with the practitioner.
Frequently Asked Questions
- Are the DEA telemedicine flexibilities ending?: They are scheduled to end on December 31, 2026. As of October 25, 2026, we found no announced extension, and a final special registration rule was under White House review.
- Can I still prescribe testosterone by telemedicine after December 31, 2026?: It depends on what DEA does. If the flexibilities lapse and nothing replaces them, our reading is that the in-person evaluation requirement returns for patients not previously evaluated in person, so confirm with counsel and your medical director.
- Will DEA extend the flexibilities again?: Unknown. DEA has extended at the last minute before, and nothing has been announced.
- What is the special registration?: A proposed DEA registration for telemedicine prescribing of controlled substances, with a DEA-issued state registration for each state where patients are treated. The final rule has not been published.
- Does this affect GLP-1 medications like semaglutide?: No. Semaglutide and tirzepatide are not controlled substances, so this change does not apply to them.
This article is general educational information, not legal advice. The dates and rules described were accurate as of October 25, 2026 and several are still pending or projected, so confirm current status with your medical director and health care regulatory counsel before making a decision.
MedGrid MSO provides management services to independently owned practices; it does not practise medicine and does not direct clinical decisions. Requirements vary by state and by service, and change over time — nothing on this page is legal or medical advice. Talk to us or your own counsel before making a structural decision for your clinic.